Washington University School of Medicine

Washington University School of Medicine in St. Louis is radically advancing immunotherapy treatments and personalized cancer therapies. PICI researcher Robert D. Schreiber, PhD, has championed the power of immunotherapy for more than 25 years. He translates basic research principles into clinical trials and drives new therapeutic approaches. Matthew Gubin, PhD, Parker Bridge Scholar, works in Schreiber’s lab researching tumor growth and rejection to improve responses to checkpoint blockade therapies. Together with PICI, they focus on T-cells and activating responses for more patients and more cancer types.

Robert D. Schreiber, PhD | Investigator
Matthew Gubin, PhD | Bridge Scholar